Haematology 2018

RELEVANCE: TREATMENT-EMERGENT ADVERSE EVENTS

TEAEs for R 2 (n = 507), %

TEAEs for R-chemo (n = 503), %

Any event Neutropenia* Anemia* Thrombocytopenia* Nausea Constipation Fatigue Asthenia Cutaneous reactions* - Rash Diarrhea Vomiting Bronchitis Peripheral neuropathy Pyrexia Cough Back pain Abdominal pain Pruritus Alopecia Febrile neutropenia Tumor flare reaction Tumor lysis syndrome

100

80

60

40

20

0

0

20

40

60

80

100

TEAEs, %

TEAEs, %

Grade 3/4

Any grade

Data cut-off31May2017. Includesany-gradeTEAEs (≥15%) and select AEs of interest as assessed per NCI CTCAE v4.03. *HematologicAEs were based on laboratorytests; all anemia events were grade 1. Cutaneous reactions included preferredterms from skin and subcutaneous tissue disorders (includingrash), gastrointestinal disorders, general disorders and administrationsite conditions,infectionsand infestations,and reproductivesystem and breast disorders. Fowleret al. RELEVANCE: Phase III Randomized Study of LenalidomidePlus Rituximab (R 2 ) Versus ChemotherapyPlus Rituximab,Followedby RituximabMaintenance,in PatientsWithPreviously Untreated Follicular Lymphoma. Oral presentationat: AmericanSociety of Clinical Oncology meeting.2018; Jun 1-5; Chicago,IL. Abstract 7500.